Genetic polymorphisms of FADS1, FADS2, and FADS3 and fatty acid profiles in subjects received methadone maintenance therapy.
Abnormal fatty acid metabolism and the related enzymes had been observed to be associated with psychiatric disorders. We investigated FADS gene family genetic polymorphisms and variations of lipid profiles in patients with heroin dependence receiving 6-month methadone maintenance therapy (MMT). We recruited 89 MMT drug abusers and analyzed 3 tag single nucleotide polymorphisms (SNPs) from Fatty acid desaturases (FADS), FADS1, FADS2 and FADS3. The fatty acid profiles of erythrocyte membranes were analyzed based on genetic variations. Six-month MMT therapy were significantly associated with decreased C20: 5n3 and C22:4n6 levels in the whole group of drug abusers. The decreases of C22: 6n3 after MMT therapy were associated with specific genetic variations, including FADS1 C/C, FADS2 T/T and FADS3 C/C genotypes. The variations on n3 and n6 PUFA composition were significantly shown in different alleles of FADS in MMT drug abusers. Further studies are needed to elucidate the role of fatty acid metabolism on rehabilitation by MMT.
['Yang|Hui-Ting|HT|', 'Wang|Ruey-Yun|RY|', 'Huang|Shih-Yi|SY|', 'Huang|Chieh-Liang|CL|', 'Su|Kuan-Pin|KP|']
D000293:Adolescent D000328:Adult D000090943:Delta-5 Fatty Acid Desaturase D044943:Fatty Acid Desaturases D005227:Fatty Acids D005260:Female D006556:Heroin Dependence D006801:Humans D008297:Male D008691:Methadone D000071184:Pharmacogenomic Variants D020641:Polymorphism, Single Nucleotide D016896:Treatment Outcome D055815:Young Adult
Methadone Heroin PUFA DHA FADS gene polymorphism